Cagrilintide 10mg

Cagrilintide 10mg

Cagrilintide – Research Grade Peptide

Cagrilintide (RUO) | High Purity ≥99% | Research Grade

Product Specifications

What Is Cagrilintide?

Cagrilintide is a long-acting, acylated analogue of the pancreatic hormone amylin. It is designed as a dual agonist of amylin receptors (AMYR) and the calcitonin receptor (CTR). Identified by CAS Number 1415456-99-3, Cagrilintide has been extensively studied in preclinical and clinical research for its effects on satiety signaling, food intake regulation, and body weight modulation.

Unlike native amylin, which has a short half-life and a high propensity to form amyloid fibrils, Cagrilintide incorporates structural modifications (including lipidation) that improve stability, reduce fibril formation, and extend duration of action. These features support once-weekly administration protocols in research models.

Cagrilintide is commonly utilized by researchers investigating amylin pathway pharmacology, dual amylin/calcitonin receptor agonism, and combination strategies with incretin-based peptides such as semaglutide (often referred to in literature as CagriSema).

This product is clearly labeled and distributed strictly as a Research Use Only (RUO) material and is not approved for human or veterinary use.

Experimental Research Applications

In scientific literature, Cagrilintide has been investigated in a variety of experimental settings, including:

• Amylin receptor (AMYR) and calcitonin receptor (CTR) dual agonism studies
• Satiety signaling and food intake regulation research
• Body weight and energy balance mechanism studies
• Gastric emptying and postprandial glucagon suppression models
• Combination research with GLP-1 receptor agonists (e.g., semaglutide / CagriSema)
• Comparative studies versus native amylin and earlier amylin analogues (e.g., pramlintide)
• Obesity and metabolic research models
• Long-acting peptide design and albumin-binding strategy investigations

These studies are conducted exclusively within laboratory and preclinical environments and are intended for mechanistic and observational research purposes.

Purity and Quality Control

Each batch of Cagrilintide undergoes analytical testing to ensure:

✔ ≥99% purity verified by HPLC ✔ LC-MS molecular weight and sequence identity confirmed per batch ✔ Batch-to-batch consistency ✔ Professional documentation and traceability ✔ Controlled manufacturing standards ✔ Reliable performance for repeatable research applications

High analytical purity and strict quality control procedures help provide researchers with confidence in the consistency and reliability of each batch.

Key Research Features

• Long-acting acylated amylin analogue
• Dual agonist of amylin receptors (AMYR) and calcitonin receptor (CTR)
• Designed for improved stability and reduced fibril formation
• Supports once-weekly research protocols
• ≥99% HPLC-verified purity
• LC-MS sequence and molecular weight identity confirmed
• Lyophilized powder format
• Suitable for in vitro and preclinical research
• Batch-tested for consistency
• Research-grade manufacturing standards
• Professionally labeled and documented

Storage Recommendations

To maintain product stability and research integrity, Cagrilintide should be:

• Stored at −20°C in a tightly sealed container
• Protected from light and moisture
• Reconstituted in sterile or bacteriostatic water
• Kept sealed until use
• Handled according to standard laboratory procedures
• Not subjected to repeated freeze-thaw cycles

Toxicology and Regulatory Information

• Currently an investigational compound under clinical evaluation
• Not FDA-approved for any therapeutic indication as of current date
• Supplied strictly as a Research Use Only (RUO) material

Why Choose Summit Pep Labs?

At Summit Pep Labs, we are committed to supplying researchers with premium-quality compounds manufactured to rigorous analytical standards.

Why Researchers Choose Summit Pep Labs

• ≥99% HPLC-verified purity
• LC-MS sequence and molecular weight identity confirmed per batch
• Batch consistency and traceability
• Professional labeling and packaging
• Research-grade manufacturing standards
• Secure cold-chain shipping and quality assurance
• Commitment to reproducibility and reliability

Frequently Asked Questions

What is Cagrilintide? Cagrilintide is a long-acting acylated amylin analogue that acts as a dual agonist of amylin receptors (AMYR) and the calcitonin receptor (CTR). It is studied in research related to satiety, food intake regulation, and metabolic pathways.

How does Cagrilintide differ from native amylin? Native amylin has a short half-life and a tendency to form amyloid fibrils. Cagrilintide incorporates structural modifications, including lipidation, that improve stability, reduce fibril formation, and extend duration of action in research models.

Is Cagrilintide the same as CagriSema? No. Cagrilintide is the amylin analogue itself. CagriSema refers to the investigational combination of cagrilintide with semaglutide that has been evaluated in clinical research.

Is Cagrilintide approved for human use? No. Cagrilintide is an investigational compound and has not received FDA approval for any therapeutic indication. It is supplied exclusively as a Research Use Only (RUO) material.

What purity does Summit Pep Labs provide? Each batch of Cagrilintide is tested and verified to contain ≥99% purity using HPLC analytical methods, with LC-MS identity confirmation performed per batch.

How is Cagrilintide supplied? Cagrilintide is supplied as a lyophilized powder and packaged according to professional research standards.

How should Cagrilintide be stored? Store at −20°C, protected from light and moisture. Reconstitute with sterile or bacteriostatic water. Avoid repeated freeze-thaw cycles.

References

• Kruse T et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021
• Lau DCW et al. Once-weekly cagrilintide for weight management. The Lancet. 2021
• Cao et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications. 2025
• PubChem Compound Summary — Cagrilintide. CID 171397054
• National Center for Biotechnology Information (NCBI)
• U.S. Food and Drug Administration (FDA) — Investigational Framework

Research Use Only Disclaimer

For Research Use Only (RUO).

This product is intended strictly for laboratory and scientific research purposes. It is not intended for human consumption, veterinary use, cosmetic applications, therapeutic use, or diagnostic purposes.

By purchasing this product, customers acknowledge that they are qualified researchers and agree to use these materials in accordance with all applicable laws and regulations.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Retatrutide vs Cagri